A multicenter study evaluating the efficacy and safety of 12 weeks versus 24 weeks peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naive patients with chronic hepatitis C genotype 2 or 3 infection

Trial Profile

A multicenter study evaluating the efficacy and safety of 12 weeks versus 24 weeks peginterferon alfa-2a 40KD combination therapy with ribavirin in interferon naive patients with chronic hepatitis C genotype 2 or 3 infection

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2011

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 24 May 2007 The expected completion date for this trial is now 1 Oct 2006.
    • 20 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top